Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus

被引：0
作者：
Camafort-Babkowski, Miguel [1 ]
机构：
[1] Univ Barcelona, Hosp Clin IDIBAPS, Inst Clin Med & Dermatol, Unidad Hipertens & Riesgo Vasc,Serv Med Interna, Barcelona, Spain
来源：
MEDICINA CLINICA | 2013年 / 141卷 / 04期
关键词：
Type 2 diabetes mellitus; Glucagon-like peptide-1; Cardiovascular risk; GLYCEMIC CONTROL; EXENATIDE TWICE; OPEN-LABEL; PARALLEL-GROUP; LIRAGLUTIDE; SAFETY; METFORMIN; ANALOGS; SITAGLIPTIN; EFFICACY;
D O I：
10.1016/j.medcli.2012.11.016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Anti-diabetic drugs have, in addition to their well-known glucose lowering-effect, different effects in the rest of cardiovascular factors that are associated with diabetes mellitus. Glucagon-like peptide-1 (GLP-1) receptor agonists have recently been incorporated to the therapeutic arsenal of type 2 diabetes mellitus. The objective of this review is to summarize the available evidence on the effect of the GLP-1 receptor agonists on different cardiovascular risk factors, mediated by the effect of GLP-1 receptor agonists on the control of hyperglycaemia and the GLP-1 receptor agonists effect on other cardiovascular risk factors (weight control, blood pressure control, lipid profile and all other cardiovascular risk biomarkers). In addition, we present the emerging evidence with regards to the impact that GLP-1 receptor agonists therapy could have in the reduction of cardiovascular events and the currently ongoing studies addressing this issue. (C) 2012 Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码：167 / 174
页数：8
相关论文
共 37 条
  • [1] [Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]
  • [2] The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review
    Aroda, Vanita R.
    Ratner, Robert
    [J]. DIABETES-METABOLISM RESEARCH AND REVIEWS, 2011, 27 (06) : 528 - 542
  • [3] Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
    Best, Jennie H.
    Hoogwerf, Byron J.
    Herman, William H.
    Pelletier, Elise M.
    Smith, Daniel B.
    Wenten, Made
    Hussein, Mohamed A.
    [J]. DIABETES CARE, 2011, 34 (01) : 90 - 95
  • [4] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
    Buse, John B.
    Rosenstock, Julio
    Sesti, Giorgio
    Schmidt, Wolfgang E.
    Montanya, Eduard
    Brett, Jason H.
    Zychma, Marcin
    Blonde, Lawrence
    [J]. LANCET, 2009, 374 (9683) : 39 - 47
  • [5] Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes
    Courreges, J. -P.
    Vilsboll, T.
    Zdravkovic, M.
    Le-Thi, T.
    Krarup, T.
    Schmitz, O.
    Verhoeven, R.
    Buganova, I.
    Madsbad, S.
    [J]. DIABETIC MEDICINE, 2008, 25 (09) : 1129 - 1131
  • [6] Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis
    Deacon, C. F.
    Mannucci, E.
    Ahren, B.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (08) : 762 - 767
  • [7] DeFronzo RA, 2010, DIABETES CARE, V33, P951, DOI [10.2337/dc09-1521, 10.2337/dc10-0646]
  • [8] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    Drucker, Daniel J.
    Buse, John B.
    Taylor, Kristin
    Kendall, David M.
    Trautmann, Michael
    Zhuang, Dangliang
    Porter, Lisa
    [J]. LANCET, 2008, 372 (9645) : 1240 - 1250
  • [9] The biology of incretin hormones
    Drucker, DJ
    [J]. CELL METABOLISM, 2006, 3 (03) : 153 - 165
  • [10] GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
    Esposito, K.
    Mosca, C.
    Brancario, C.
    Chiodini, P.
    Ceriello, A.
    Giugliano, D.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (08) : 1519 - 1528
1234